Research

Disclaimer: All information on this section is of a general nature.
Before making any investment decision, you should consult your adviser.

Investment Ideas: BARD1 (BD1) test results success

 

BARD1 Life Sciences (ASX:BD1) announced on 23 March, 2017, that the group’s proprietary ovarian cancer diagnostic test was successful in a recently completed clinical trial involving 348 samples.


In the announcement released to the ASX, CEO Dr Leearne Hinch states: “With high levels of accuracy shown to all stages of ovarian cancer, our test may offer a substantial improvement over existing ovarian cancer blood tests using CA 125 where both sensitivity and specificity are lower”. 

·   At current share price levels of A$4.8cps we believe that BD1 offers significant upside potential. Recommendation:Speculative Buy (Higher Risk).

 
24/03/2017 11:07:54 AM

Back to top